CellPro Inc. said that it has introduced two new Ceprate LC kitsfor cellular research. The kits purify T-helper (CD4) and T-suppressor (CD8) cells for research studies.

In October, the Bothell, Wash., company (NASDAQ:CPRO)introduced its first kit, for the purification of stem cells.

CellPro estimates the annual world market for research cellseparations at $50 million to $75 million. The company's stocklost 25 cents to $11.75 on Wednesday.

(c) 1997 American Health Consultants. All rights reserved.